Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
തുറക്കുക
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.21%
1,091.51
-2.30
-0.21%
—1,093.811,096.521,100.221,091.51——
SIXC
Communications
SIXC
Communications
SIXC
+0.22%
610.11
+1.34
+0.22%
—608.77608.77612.97608.77——
SIXE
Energy
SIXE
Energy
SIXE
-1.34%
1,237.98
-16.83
-1.34%
—1,254.811,253.011,253.871,226.33——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.93%
1,744.71
-16.40
-0.93%
—1,761.111,764.271,766.881,744.71——
SIXM
Financials
SIXM
Financials
SIXM
-0.37%
640.18
-2.40
-0.37%
—642.58644.87648.48640.18——
SIXR
Staples
SIXR
Staples
SIXR
-0.18%
849.58
-1.55
-0.18%
—851.13855.66858.75845.56——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.23%
217.48
-0.50
-0.23%
—217.98217.98218.65216.88——
SIXT
Technology
SIXT
Technology
SIXT
+1.52%
3,260.69
+48.86
+1.52%
—3,211.833,227.213,268.383,226.55——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.69%
942.45
-6.53
-0.69%
—948.98948.58957.83941.97——
SIXV
Health care
SIXV
Health care
SIXV
-0.52%
1,466.80
-7.72
-0.52%
—1,474.521,479.031,481.041,466.80——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.22%
2,397.50
+5.38
+0.22%
—2,392.122,396.952,421.222,382.32——
GNLX:NASDAQ
Genelux Corp
$2.74
+2.62%
(+0.070) 1D
മേയ് 1, ജിഎംടി-4 4:00:01 PM  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GNLX...
തുറക്കുക
$2.63
High
$2.75
Low
$2.63
Mkt. cap
൧൨൨.൮൭M
Avg. vol.
൨൧൦.൬൦K
Volume
൧൧൮.൦൬K
52-wk high
$8.54
52-wk low
$2.26
EPS
-$0.86
Beta
൦.൪൮
Shares outstanding
൪൪.൮൧M
No. of employees
൨൬
News stories
From sources across the web
പ്രൊഫൈൽ
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
About Genelux Corp
CEO-
Employees26
Founded2001
Headquartersവെസ്റ്റ്‍ലേക്ക് വില്ലേജ്, കാലിഫോർണിയ, അമേരിക്ക
Sector-
Websitegenelux.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
2025 മാർ
2025 ജൂൺ
2025 സെപ്റ്റം
2025 ഡിസം
Revenue
-
-
-
8.00K
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
4.70M
4.76M
4.74M
5.55M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.12M
3.03M
3.45M
3.87M
Operating expense
7.82M
7.79M
8.19M
9.42M
Total operating expenses
7.82M
7.79M
8.19M
9.42M
Operating income
-7.82M
-7.79M
-8.19M
-9.41M
Other non operating income
140.00K
112.00K
69.00K
37.00K
EBT including unusual items
-7.49M
-7.46M
-7.95M
-9.25M
EBT excluding unusual items
-7.49M
-7.46M
-7.95M
-9.25M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-7.49M
-7.46M
-7.95M
-9.25M
Net profit margin
-
-
-
-115,587.50%
Earnings per share
-0.21
-0.20
-0.21
-0.24
Interest and investment income
184.00K
224.00K
175.00K
128.00K
Interest expense
-
-
-
-
Net interest expenses
184.00K
224.00K
175.00K
128.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-7.76M
-7.73M
-8.13M
-9.35M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer